Gallus BioPharmaceuticals Uses ambr15 Micro Bioreactor to Develop Novel Antibodies and Biosimilars

Apr 30, 2014
By BioPharm International Editors

TAP Biosystems, now part of the Sartorius Stedim Biotech Group, a supplier of cell culture and fermentation systems for life science applications, announced that CMO Gallus BioPharmaceuticals is using its ambr15 micro bioreactor system to optimize process development and clone selection of novel antibody therapeutics and biosimilars.

Scientists at Gallus BioPharmaceuticals are using the ambr15 micro bioreactor in the company’s new, state-of-the-art process development facility in St. Louis, Missouri. The system is being used for clone selection programs to determine which CHO cell lines are stable and produce the highest titre mAbs. The scientists are also using the ambr system to optimize media selection and feed strategies for these mAbs, which are being developed as antibody therapeutics and biosimilars for some of the world’s top pharma and biotech firms.

Source: TAP Biosystems